PLUVICTO® for progressive PSMA-positive metastatic castration-resistant prostate cancer^3a

PLUVICTO® (lutetium [¹⁷⁷Lu] vipivotide tetratextan) is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy that targets PSMA-positive cells, including cancer cells.^{3b 4}

In the European Union, PLUVICTO® in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy.^3c

LUTATHERA^Ⓡ for neuroendocrine tumours (NETs)

LUTATHERA^Ⓡ (lutetium (¹⁷⁷Lu) oxodotreotide) is a peptide receptor radionuclide therapy (PRRT). It is composed of the radionuclide lutetium-177 (¹⁷⁷Lu) and the somatostatin analogue oxodotreotide that targets somatostatin receptor-positive cells, including neuroendocrine tumour cells.^{1c 5 6a}

LUTATHERA^Ⓡ is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. ^6b

LOCAMETZ^Ⓡ for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer^8a

LOCAMETZ^Ⓡ is a kit for the radiopharmaceutical preparation of gallium (⁶⁸Ga) gozetotide.^8b

LOCAMETZ^Ⓡ, after radiolabelling with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography in adults with prostate cancer in the following clinical settings:^8c

• Primary staging of patients with high-risk prostate cancer prior to primary curative therapy, 
• Suspected prostate cancer recurrence in patients with increasing levels of serum prostate-specific antigen after primary curative therapy, 
• Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer for whom PSMA-targeted therapy is indicated

Using LOCAMETZ^Ⓡ may help you determine if your patient is eligible for PSMA-targeted radioligand therapy^8d

NETSPOT^Ⓡ for the detection of somatostatin receptor-positive neuroendocrine tumours^9a

NETSPOT^Ⓡ is a kit containing non-radioactive components used to prepare a radiopharmaceutical product using gallium (⁶⁸Ga) chloride solution before it is administered intravenously.^9b

In the European Union, after radiolabelling with gallium-68, NETSPOT^Ⓡ is indicated for use as a radioactive diagnostic agent in positron emission tomography imaging to localise somatostatin receptor-positive neuroendocrine tumours in adult and paediatric patients.^9c

SomaKit TOC^Ⓡ for imaging of gastroenteropancreatic neuroendocrine tumours (GEP-NETs)^10a

SomaKit TOC^Ⓡ is a 40 micrograms kit for the radiopharmaceutical preparation of gallium (⁶⁸Ga) edotreotide solution for injection.^10b

This medicinal product is for diagnostic use only.^10c

After radiolabelling with gallium-68 (⁶⁸Ga) chloride solution using SomaKit TOC^Ⓡ, the solution of gallium (⁶⁸Ga) edotreotide is indicated for positron emission tomography imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours, to localise primary tumours and their metastases.^10d